IHP-102 is a novel dual P-selectin and complement inhibitor, which are two key mechanisms of vaso-occlusion in sickle cell disease. During acute vaso-occlusive pain crises, blockade of these mechanisms shows strong promise for disease-modifying effect and could reduce both pain symptoms and the tissue and organ damage cause by this devastating condition.